| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
One hundred questions of importance to the conservation of global biological diversity.
|
Conserv Biol
|
2009
|
3.95
|
|
2
|
The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials.
|
Stat Med
|
1999
|
3.53
|
|
3
|
Evidence for a complex regulatory array in the first intron of the human adenosine deaminase gene.
|
Genes Dev
|
1989
|
1.93
|
|
4
|
The pharmaceutical industry and health reform: lessons from Europe.
|
Health Aff (Millwood)
|
1994
|
1.81
|
|
5
|
A systematic review of the staging performance of endoscopic ultrasound in gastro-oesophageal carcinoma.
|
Gut
|
2001
|
1.72
|
|
6
|
Desk top analysers in general medical practice: how useful are they?
|
Med Lab Sci
|
1990
|
1.48
|
|
7
|
Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy.
|
Support Care Cancer
|
2005
|
1.48
|
|
8
|
Randomised controlled trial comparing endometrial resection with abdominal hysterectomy for the surgical treatment of menorrhagia.
|
Br J Obstet Gynaecol
|
1993
|
1.47
|
|
9
|
Systematic review of utilities in abdominal aortic aneurysm.
|
Eur J Vasc Endovasc Surg
|
2008
|
1.42
|
|
10
|
Cost effectiveness of eptifibatide in acute coronary syndromes; an economic analysis of Western European patients enrolled in the PURSUIT trial. The Platelet IIa/IIb in unstable Angina: Receptor Suppression Using Integrilin Therapy.
|
Eur Heart J
|
2002
|
1.40
|
|
11
|
Developing guidance for budget impact analysis.
|
Pharmacoeconomics
|
2001
|
1.40
|
|
12
|
In vivo activity and in vitro specificity of CD4+ Th1 and Th2 cells derived from the spleens of diabetic NOD mice.
|
J Clin Invest
|
1995
|
1.36
|
|
13
|
A comparison of the costs and survival of hospital-admitted stroke patients across Europe.
|
Stroke
|
2001
|
1.27
|
|
14
|
Initial results of screening of nondiabetic organ donors for expression of islet autoantibodies.
|
J Clin Endocrinol Metab
|
2006
|
1.27
|
|
15
|
Nutrition economics - characterising the economic and health impact of nutrition.
|
Br J Nutr
|
2010
|
1.14
|
|
16
|
European School of Oncology Advisory report to the Commission of the European Communities for the "Europe Against Cancer Programme" cost-effectiveness in cancer care.
|
Eur J Cancer
|
1995
|
1.12
|
|
17
|
Cost effectiveness of treatment options in advanced breast cancer in the UK.
|
Pharmacoeconomics
|
2001
|
1.11
|
|
18
|
An economic evaluation of transcervical endometrial resection versus abdominal hysterectomy for the treatment of menorrhagia.
|
Br J Obstet Gynaecol
|
1993
|
1.09
|
|
19
|
16-aryloxyprostaglandins: a new class of potent luteolytic agent.
|
Prostaglandins
|
1974
|
1.08
|
|
20
|
Cost-effectiveness analysis comparing epidural, patient-controlled intravenous morphine, and continuous wound infiltration for postoperative pain management after open abdominal surgery.
|
Br J Anaesth
|
2012
|
1.05
|
|
21
|
Differential splicing of the IA-2 mRNA in pancreas and lymphoid organs as a permissive genetic mechanism for autoimmunity against the IA-2 type 1 diabetes autoantigen.
|
Diabetes
|
2001
|
1.03
|
|
22
|
Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom.
|
Anaesthesia
|
2005
|
1.02
|
|
23
|
Economic evaluation of healthcare: a half-way technology.
|
Health Econ
|
1994
|
1.01
|
|
24
|
Genetic association of zinc transporter 8 (ZnT8) autoantibodies in type 1 diabetes cases.
|
Diabetologia
|
2012
|
1.00
|
|
25
|
Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients.
|
Anticancer Drugs
|
1998
|
1.00
|
|
26
|
Isolation and sequence analysis of cDNA for rat carboxypeptidase E [EC 3.4.17.10], a neuropeptide processing enzyme.
|
Mol Endocrinol
|
1989
|
0.98
|
|
27
|
Treatment pathways, resource use and costs in the management of small cell lung cancer.
|
Thorax
|
2001
|
0.97
|
|
28
|
The identification of bias in studies of the diagnostic performance of imaging modalities.
|
Br J Radiol
|
1997
|
0.97
|
|
29
|
Identifying studies for systematic reviews. An example from medical imaging.
|
Int J Technol Assess Health Care
|
2000
|
0.95
|
|
30
|
One year comparison of costs of coronary surgery versus percutaneous coronary intervention in the stent or surgery trial.
|
Heart
|
2004
|
0.92
|
|
31
|
Workshop Report: concepts and methods in the economics of nutrition--gateways to better economic evaluation of nutrition interventions.
|
Br J Nutr
|
2012
|
0.91
|
|
32
|
A nice challenge for health economics.
|
Health Econ
|
2000
|
0.88
|
|
33
|
Folic acid supplements to prevent neural tube defects: trends in East of Ireland 1996-2002.
|
Ir Med J
|
2004
|
0.88
|
|
34
|
Comparison of a complement fixation test, a gel diffusion test and two absorbed and unabsorbed ELISAs for the diagnosis of paratuberculosis in sheep.
|
Vet Microbiol
|
1994
|
0.88
|
|
35
|
Systematic review of endoscopic ultrasound in gastro-oesophageal cancer.
|
Health Technol Assess
|
1998
|
0.86
|
|
36
|
A comparison of the cost-effectiveness of stroke care provided in London and Copenhagen.
|
Int J Technol Assess Health Care
|
2000
|
0.85
|
|
37
|
Intravascular ultrasound-guided interventions in coronary artery disease: a systematic literature review, with decision-analytic modelling, of outcomes and cost-effectiveness.
|
Health Technol Assess
|
2000
|
0.85
|
|
38
|
Utility of health states in chronic kidney disease: a structured review of the literature.
|
Curr Med Res Opin
|
2008
|
0.84
|
|
39
|
Palliative radiotherapy--counting the costs of changing practice.
|
Health Policy
|
1991
|
0.84
|
|
40
|
Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole.
|
Pharmacoeconomics
|
1999
|
0.83
|
|
41
|
A comparison of the costs and benefits of recombinant human erythropoietin (epoetin) in the treatment of chronic renal failure in 5 European countries.
|
Pharmacoeconomics
|
1992
|
0.82
|
|
42
|
Candida peritonitis and cimetidine.
|
Lancet
|
1978
|
0.81
|
|
43
|
What is the cost of radiotherapy?
|
Eur J Radiol
|
1991
|
0.80
|
|
44
|
Ranking and selection of MII oocytes in human ICSI cycles using gene expression levels from associated cumulus cells.
|
Hum Reprod
|
2013
|
0.79
|
|
45
|
Suppurative thrombarteritis as a complication of arterial cannulation: case report.
|
Mil Med
|
1984
|
0.78
|
|
46
|
Meta-analysis, overviews and publication bias.
|
Stat Methods Med Res
|
2001
|
0.77
|
|
47
|
Cost-benefit analysis in health care expenditure decision-making.
|
Health Econ
|
1992
|
0.77
|
|
48
|
Measurements of blood pressure, oedema and proteinuria in a pregnant population of New Zealand.
|
Aust N Z J Obstet Gynaecol
|
1995
|
0.77
|
|
49
|
Changes in cost-effectiveness over time. The case of Epoetin Alfa for renal replacement therapy patients in the UK.
|
Eur J Health Econ
|
2003
|
0.77
|
|
50
|
A systematic literature review of spiral and electron beam computed tomography: with particular reference to clinical applications in hepatic lesions, pulmonary embolus and coronary artery disease.
|
Health Technol Assess
|
1999
|
0.77
|
|
51
|
Modeling in economic evaluation: an unavoidable fact of life.
|
Health Econ
|
1998
|
0.75
|
|
52
|
Adult respiratory distress syndrome secondary to tularemia pneumonia.
|
Arch Intern Med
|
1985
|
0.75
|
|
53
|
House Bill 1012: perspective on new HIV law.
|
J Okla State Med Assoc
|
1992
|
0.75
|
|
54
|
Haematometra caused by hormone replacement therapy after endometrial resection.
|
Lancet
|
1991
|
0.75
|
|
55
|
Polishing your success image--what makes a QA professional marketable.
|
J Qual Assur
|
1988
|
0.75
|
|
56
|
Budgetary control-the role of the director of nursing services and treasurers.
|
Nurs Times
|
1982
|
0.75
|
|
57
|
History of high-velocity impact water trauma at Letterman Army Medical Center: a 54-year experience with the Golden Gate Bridge.
|
Mil Med
|
1995
|
0.75
|
|
58
|
Diet and obesity.
|
Fortn Rev Chic Dent Soc
|
1966
|
0.75
|
|
59
|
High tech for hire.
|
Health Soc Serv J
|
1983
|
0.75
|
|
60
|
Cost-effectiveness analysis for statin therapies in the primary prevention of coronary heart disease in Italy.
|
Clin Drug Investig
|
2000
|
0.75
|
|
61
|
Synthesis and biological activity of 15-arylprostaglandins.
|
Prostaglandins
|
1978
|
0.75
|
|
62
|
Should free personal care be available for all older people?
|
Nurs Times
|
2002
|
0.75
|
|
63
|
Evaluation of cariostatic disciplines for postradiation caries.
|
Caries Res
|
1982
|
0.75
|
|
64
|
THRM forum: Challenge for medical record managers.
|
Top Health Rec Manage
|
1985
|
0.75
|
|
65
|
A Markov model of treatment of newly diagnosed epilepsy in the UK. An initial assessment of cost-effectiveness of topiramate.
|
Eur J Health Econ
|
2003
|
0.75
|
|
66
|
Highest ADA expressing mouse tissues also exhibit cell-type specific coordinate up-regulation of purine degradative enzymes.
|
Adv Exp Med Biol
|
1991
|
0.75
|
|
67
|
Double agents. Interview by Maura Thompson.
|
Health Serv J
|
2000
|
0.75
|
|
68
|
Oestrogens after the menopause.
|
Midwife Health Visit Community Nurse
|
1978
|
0.75
|
|
69
|
Assessing technology for rehabilitation. Three cases and three countries.
|
Int J Technol Assess Health Care
|
1987
|
0.75
|
|
70
|
Regulation of the human adenosine deaminase gene by first intron sequences: a T-cell enhancer.
|
Adv Exp Med Biol
|
1991
|
0.75
|
|
71
|
Polishing your image for success as health information management professionals.
|
J AHIMA
|
1992
|
0.75
|
|
72
|
Technology and the structure of the UK radiological equipment industry since 1945.
|
Soc Soc Hist Med Bull (Lond)
|
1987
|
0.75
|
|
73
|
Economic evaluation of medical technologies.
|
Int J Technol Assess Health Care
|
1986
|
0.75
|
|
74
|
Health care reform: the search for the holy grail.
|
Health Econ
|
1992
|
0.75
|
|
75
|
Total synthesis of prostaglandins E2 and F2-alpha (dl) via a tricarbocyclic intermediate.
|
Tetrahedron Lett
|
1970
|
0.75
|
|
76
|
Economic evaluation of trends in cancer therapy. Marginal or average costs?
|
Int J Technol Assess Health Care
|
1991
|
0.75
|
|
77
|
Living with a facial prosthesis. A guide to patient care.
|
Am J Nurs
|
1984
|
0.75
|